Tumor suppressive action of indomethacin is NK-cell-independent.
This study was undertaken to determine whether NK-cells constitute a necessary mediator for the suppression of tumor growth by indomethacin. C57Bl mice with a methylcholantrene (MCG 101) tumor were studied. Indomethacin treatment was provided by daily subcutaneous injections (1 microgram/g body weight). NK-cells were depleted by treatment with a monoclonal antibody to NK1.1. Consecutive indomethacin injections prolonged survival in tumor bearing animals. Indomethacin was equally effective in animals with intact NK-cells as in NK-cell-depleted animals. Further, the MCG cells were apparently insensitive to the lytic activity of NK-cells in vivo. Thus, the clearance of intravenously injected MCG cells from lungs was not affected by depletion of NK-cells in vivo; in contrast, the corresponding clearance of NK-cell-sensitive YAC-1 lymphoma cells was strikingly reduced by the depletion of NK-cells. Our data suggest that NK cells are not a necessary mediator for the suppression of tumor growth by indomethacin.
Cvetkovska
E
E
Department of Otolaryngology, Head and Neck Surgery, Sahlgrenska Hospital, University of Göteborg, Sweden.
Asea
A
A
Hellstrand
K
K
Edström
S
S
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D003602:Cytotoxicity, Immunologic; D005260:Female; D007213:Indomethacin / Q000494:pharmacology*; D007694:Killer Cells, Natural / Q000502:physiology*; D008212:Lymphocyte Depletion; D008223:Lymphoma / Q000188:drug therapy; D051379:Mice; D008810:Mice, Inbred C57BL; D012513:Sarcoma, Experimental / Q000188:drug therapy* / Q000276:immunology
D000970:Antineoplastic Agents; D007213:Indomethacin